Phillips James Michael, SVP, Research & Development, subtracted 7,231 shares of Pacific Biosciences of California, Inc. (PACB) from its portfolio at the rate of $7.17 per share valuing $51,817 on Feb 19. The insider left behind 229,530 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Pacific Biosciences of California, Inc. (PACB) was $6.66. Currently, the 1st Resistance Point for this stock is $6.82, with a 2nd Resistance Point sitting at $6.97. Meanwhile, this company’s stock has a 1st Support Level at $6.48 and a 2nd Support Level at $6.30. Pacific Biosciences of California, Inc. (PACB) stock has lost -$0.25, or -3.62%, in the past five days. In the last full month, these shares have lost -$0.71, or -9.63%. In the past three months, this stock’s price has fallen by -$0.64, or -8.77%. This year-to-date, Pacific Biosciences of California, Inc. (PACB) shares have lost -$0.74, or -10.00%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Pacific Biosciences of California, Inc. (PACB) stock, 80% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”
With 152,675 K shares outstanding, this company currently has a market capitalization of $1,029,030K. Pacific Biosciences of California, Inc. (PACB) generates $78,630 K in annual sales, amounting to annual net income of -$102,560 K. This stock has generated a 1-Year Total Return of 102.43%, a 3-Year Total Return of -22.92%, and a 5-year Total Return of 2.62%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.17 per share. This estimate came from a total of 2 Wall Street Analysts. Of those market experts, the high estimate was -$0.16 and the low estimate was -$0.19. In the year-ago quarter, Pacific Biosciences of California, Inc. (PACB) generated per-share earnings of -$0.17.
Turning our focus now to insider trading activity, there have been 1 purchases (7,500 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 11 insider buys amounting to 468,795 shares and 4 insider sales amounting to 39,486 shares. In the past full year, 13 insider purchases were made (involving 493,796 shares) and 5 insider sell-offs equivalent to 64,486 shares.
Moving onto liquidity, Pacific Biosciences of California, Inc. (PACB) has a Current Ratio of 4.90, a Quick Ratio of 4.23 and a Cash Ratio of 3.81. Looking at this company’s capital structure, its Total Debt to Total Equity is 12.85, its Total Debt to Total Capital is 11.39, and its Total Debt to Total Assets is now 8.61. Looking even further ahead into the future, its Long-Term Debt to Equity is 12.85 and its Long-Term Debt to Total Capital is 11.39.